Ornithine transcarbamylase deficiency (OTC deficiency) is a rare, inherited metabolic disorder caused by a deficiency of the enzyme ornithine transcarbamylase. This enzyme plays a key role in the urea cycle, being one of the enzymes required to remove ammonia from the body. Deficiency of OTC results in a buildup of ammonia, which can cause acute and chronic neurological and metabolic disorders. Symptoms may begin in early childhood, but may also begin later, depending on the amount of residual enzyme activity. High levels of ammonia can cause severe conditions such as hypersomnia, vomiting, coma, and in very severe cases, death.
History of the disease and interesting historical facts
Ornithine transcarbamylase deficiency was first described in 1962 by a group of scientists who identified a link between amino acid metabolism disorders and neurological symptoms in patients. The first cases were registered in families with a high level of consanguinity, which led to further study of the characteristics and pathogenesis of the disease. The advent of genetic tests in the 1990s significantly improved the diagnosis of ORTC, allowing for the prediction and detection of the disease in newborns. An important step forward was the discovery of genes responsible for the production of ornithine transcarbamylase, which made it possible to understand the mechanisms of inheritance and conduct genetic studies.
Epidemiology
Ornithine transcarbamylase deficiency is a rare disease with an incidence of approximately 1 in 50,000 to 30,000 live births. The disease has a higher prevalence among certain ethnic groups due to hereditary factors. For example, Arab populations and some indigenous peoples in the United States have significantly higher rates of the disease. Certain populations, such as Ashkenazi Jews, have a carrier frequency of up to 1 in 25, which contributes to the accumulation of the disease in these groups.
Genetic predisposition to this disease
Ornithine transcarbamylase deficiency is caused by mutations in the OTC gene, located on the X chromosome. These mutations can vary, but most often point or small deletions occur, leading to a decrease or complete absence of enzyme activity. Both sexes have differences in the clinical manifestations of the disease, since mutations in the action of the gene located on the X chromosome can manifest themselves more severely in men than in women. Carrying one mutation in women can manifest itself with less pronounced symptoms, which complicates diagnosis.
Risk factors for the development of this disease
The main risk factor for the development of ornithine transcarbamylase deficiency is the presence of cases of the disease in the family, since DOTC is inherited in a recessive manner. Factors that contribute to the manifestation of the disease include the following:
- Use of certain medications that may affect metabolism (eg, steroids);
- External stresses such as infections or hypoglycemia;
- Pathological conditions that may increase the metabolic load, such as tumor formation;
- Liver disease and other conditions associated with ammonia metabolism.
Diagnosis of this disease
Diagnosis of ornithine transcarbamylase deficiency involves evaluation of clinical manifestations and laboratory tests. The main symptoms of the disease may include:
- Neurological disorders (including comatose states);
- Vomiting and loss of appetite;
- Hypotension and developmental delay;
- Convulsions and impaired consciousness.
Laboratory tests are primarily aimed at determining the level of ammonia and transaminases in the blood, as a rule, their parameters are significantly increased. Determination of ornithine transcarbamylase activity in a liver biopsy is mandatory, as well as genetic testing for mutations in the OTC gene. Radiological examination may include ultrasound of the abdominal organs to assess the condition of the liver and other organs. Differential diagnostics should exclude other metabolic disorders, such as arginine deficiency and other ornithine cycles.
Treatment
Treatment of ornithine transcarbamylase deficiency is aimed at reducing ammonia levels in the body and correcting metabolic disorders. The main approaches to therapy include:
- Hospitalization and immediate use of anti-ammonia measures such as hydration and correction of electrolyte balance;
- Use of a low protein diet;
- Pharmacological therapy: use of a diet rich in unsaturated amino acids and administration of drugs such as sodium benzoate;
- Surgical treatment may be required in cases where severe, life-threatening conditions such as acute liver injury occur.
List of medications used to treat this disease
Drugs that can be used to treat DOTC:
- Sodium benzoate;
- Lactulose;
- Rehydration solutions;
- Arginine and its derivatives.
Disease monitoring
Monitoring of a patient with DOTC includes regular laboratory testing of ammonia levels and liver function, as well as an assessment of general health. Prognosis depends on prompt diagnosis and adequate treatment; early intervention significantly increases the likelihood of a favorable outcome. Complications include the development of neurological impairment, severe coma, and the need for liver transplantation if the disease progresses.
Age-related features of the disease
The presentation of ornithine transcarbamylase deficiency can vary significantly depending on the age group. In neonates and infants, symptoms are more likely to present as an acute metabolic crisis with high ammonia levels. In children and adults, milder forms are possible with neurological disorders that may present later and be less severe. This highlights the importance of genetic counseling and early detection.
Questions and Answers
- What is ornithine transcarbamylase deficiency? It is an inherited disorder associated with a deficiency of an enzyme needed to remove ammonia from the body, leading to its build-up with potentially dangerous health consequences.
- What are the main symptoms of the disease? The main symptoms include vomiting, loss of appetite, neurological disorders such as coma and seizures.
- How is DOTC diagnosed? Diagnosis includes laboratory testing of ammonia levels, enzyme activity assessment, genetic testing, and tests to rule out other metabolic disorders.
- What is the treatment for ornithine transcarbamylase deficiency? Treatment includes dietary adjustments, the use of special medications to reduce ammonia levels and, if necessary, surgery.
- What factors increase the risk of disease? The main risk factors are genetic predisposition and the presence of cases of the disease in the family.
